EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Emergence of artemisinin-based combination therapy resistance markers in Plasmodium falciparum from the Brazilian tri-border region of the Guiana Shield

Yanka E A R Salazar iD, Antonio M Rezende iD, Maria C S B Puça iD, Jaime Louzada, Maria E P Mascarenhas iD, Sonja Lagström, Danielle Fletcher, Joseli Oliveira-Ferreira iD, José P Gil iD, Tais N de Sousa iD

Antimicrobial Agents and Chemotherapy · 01.04.2026 · 70 (4)

DOI: 10.1128/aac.01525-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.04.2026. Verfasst von Yanka E A R Salazar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Instituto René Rachou, Fiocruz Minas, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil. Hauptthemen laut MEDLINE: Plasmodium falciparum, Artemisinins, Antimalarials, Drug Resistance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Fundação de Amparo à Pesquisa do Estado de Minas Gerais.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasmodium falciparum malaria remains a public health concern in the Brazilian Amazon, particularly among mobile and remote populations. Antimalarial drug resistance threatens elimination efforts, particularly in the Guiana Shield, which has historically been linked to the spread of resistant parasites. We analyzed 99 P . falciparum isolates collected in Roraima State, northern Brazil (2016–2020), using targeted deep sequencing. Variants were assessed in pfcrt , pfmdr1 , and pfk13 , as well as copy number variation in pfpm2 and pfpm3 , including detection of the pfpm2/3 hybrid. High coverage enabled the detection of both dominant and minority alleles. Among the 99 isolates, the pfmdr1 -NFD haplotype was found in 6% (6/99, all likely originating from Venezuela), pfcrt -C350R in 7% (7/99), and pfpm2 and pfpm3 amplifications in 5% (5/94) and 6% (6/97), respectively, and the pfpm2/3 hybrid in 4% (4/99). No validated or candidate pfk13 mutations associated with artemisinin partial resistance were detected. This study provides the first report of the pfpm2/3 hybrid and the pfmdr1 -NFD haplotype in Brazil and confirms the presence of pfcrt -C350R in isolates from the tri-border area. These variants, associated with reduced susceptibility to lumefantrine and piperaquine, suggest that parasites in northern Brazil already carry resistance markers that are prevalent in neighboring countries. These results highlight the need for continued genomic surveillance to detect early warning signals, guide treatment policies, and contain the spread of parasites with reduced susceptibility to artemisinin-based combination therapy partner drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumArtemisininsAntimalarialsDrug ResistanceMalaria, FalciparumBrazilProtozoan ProteinsHumansATP-Binding Cassette, Sub-Family C ProteinsQuinolinesDNA Copy Number VariationsHaplotypesMembrane Transport ProteinsLumefantrineDrug Therapy, CombinationPiperazines

Stichwörter der Autor:innen

Plasmodium falciparumantimalarialsartemisinin-based combination therapiesdrug resistancemalariamolecular markernext-generation sequencing

Substanzen

ArtemisininsAntimalarialsProtozoan ProteinsartemisininATP-Binding Cassette, Sub-Family C ProteinsQuinolinesMdr1 protein, Plasmodium falciparumMembrane Transport ProteinsLumefantrinepiperaquine

Autor:innen und Institutionen

  • Instituto René Rachou, Fiocruz Minas, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.
  • Karolinska Institutet, Solna, Sweden.
  • Universidade Federal de Roraima, Boa Vista, Roraima, Brazil.
  • Agilent Technologies Sweden AB, Sundbyberg, Sweden.
  • Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
  • Institute of Hygiene and Tropical Medicine, Nova University of Lisbon, Lisbon, Portugal.

ORCID-Profile: Yanka E A R Salazar, Antonio M Rezende, Maria C S B Puça, Maria E P Mascarenhas, Joseli Oliveira-Ferreira, José P Gil, Tais N de Sousa

Förderung

  • Swedish Research Council
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais

Zitieren

APA

Salazar, Y. E. A. R., Rezende, A. M., Puça, M. C. S. B., Louzada, J., Mascarenhas, M. E. P., Lagström, S., Fletcher, D., Oliveira-Ferreira, J., Gil, J. P., & de Sousa, T. N. (2026). Emergence of artemisinin-based combination therapy resistance markers in Plasmodium falciparum from the Brazilian tri-border region of the Guiana Shield. Antimicrobial Agents and Chemotherapy, 70(4). https://doi.org/10.1128/aac.01525-25

Vancouver

Salazar YEAR, Rezende AM, Puça MCSB, Louzada J, Mascarenhas MEP, Lagström S, et al. Emergence of artemisinin-based combination therapy resistance markers in Plasmodium falciparum from the Brazilian tri-border region of the Guiana Shield. Antimicrobial Agents and Chemotherapy. 2026;70(4). doi:10.1128/aac.01525-25

BibTeX
@article{Salazar2026,
  author = {Salazar, Yanka E A R and Rezende, Antonio M and Puça, Maria C S B and Louzada, Jaime and Mascarenhas, Maria E P and Lagström, Sonja and Fletcher, Danielle and Oliveira-Ferreira, Joseli and Gil, José P and de Sousa, Tais N},
  title = {Emergence of artemisinin-based combination therapy resistance markers in Plasmodium falciparum from the Brazilian tri-border region of the Guiana Shield},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {4},
  doi = {10.1128/aac.01525-25}
}
Kostenlos starten →